Reviva Pharmaceuticals Holdings Inc (RVPH) concluded trading on Tuesday at a closing price of $1.78, with 4.27 million shares of worth about $7.6 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 43.18% during that period and on December 24, 2024 the price saw a gain of about 8.54%. Currently the company’s common shares owned by public are about 46.58M shares, out of which, 39.69M shares are available for trading.
Stock saw a price change of 27.84% in past 5 days and over the past one month there was a price change of 56.99%. Year-to-date (YTD), RVPH shares are showing a performance of -65.25% which decreased to -61.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.60 but also hit the highest price of $5.67 during that period. The average intraday trading volume for Reviva Pharmaceuticals Holdings Inc shares is 1.86 million. The stock is currently trading 3.34% above its 20-day simple moving average (SMA20), while that difference is up 27.98% for SMA50 and it goes to 5.53% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) currently have 46.58M outstanding shares and institutions hold larger chunk of about 29.03% of that.
The stock has a current market capitalization of $89.99M and its 3Y-monthly beta is at -0.07. It has posted earnings per share of -$1.11 in the same period. It has Quick Ratio of 0.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RVPH, volatility over the week remained 21.49% while standing at 23.60% over the month.
Stock’s fiscal year EPS is expected to rise by 40.00% while it is estimated to increase by 14.95% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH MKM on September 20, 2023 offering a Buy rating for the stock and assigned a target price of $12 to it. Coverage by The Benchmark Company stated Reviva Pharmaceuticals Holdings Inc (RVPH) stock as a Speculative buy in their note to investors on June 08, 2023, suggesting a price target of $17 for the stock.
